Abstract
Inherited heart diseases have experienced an exponential growth in recent years and a permanent updating is required. From the scientific production of the last year, not only original articles stand out, but also position papers, expert consensus and brief communications of in vivo gene therapy trials. Also noteworthy are the contributions in the molecular mechanisms of disease from basic research groups and extensive longitudinal series on cardiomyopathies due to mutations in specific genes that allow prognostic conclusions to be drawn. This article summarizes the most relevant findings of 2021 and 2022 with a special emphasis on clinical advances and translational research.ATTR: amiloidosis por transtirretina; ATTRv: amiloidosis por transtirretina hereditaria; FV: fibrilación ventricular; MCA: miocardiopatía arritmogénica; MCD: miocardiopatía dilatada; SBr: síndrome de Brugada.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
